Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019.

Abstract

OBJECTIVE:

 The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19).

STUDY DESIGN:

 We report 12 cases of unvaccinated pregnant patients with mild-to-moderate COVID-19 treated with casirivimab/imdevimab.

RESULTS:

 Twelve unvaccinated pregnant patients with mild-to-moderate COVID-19 received casirivimab/imdevimab at the dose of 1200/1200 mg by intravenous infusion over 60 minutes. All women were managed outpatient. None experienced severe adverse drug reaction and none progressed to severe disease.

CONCLUSION:

 Casirivimab/imdevimab should be considered for outpatient treatment of unvaccinated pregnant women with mild-to-moderate COVID-19 to decrease the risk of severe disease.

KEY POINTS:

· Casirivimab/imdevimab is not well studied in pregnant women.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 decreases the risk of severe disease.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 is well tolerated..

• Authors: Antonio Riccardo Buonomo, Isabella Di Filippo, Nunzia Esposito, Gabriele Saccone, Mariano Nobile, Giulio Viceconte, Riccardo Villari, Costantino Di Carlo, Giuseppe Bifulco, Ivan Gentile
• Journal: American journal of perinatology (Am J Perinatol) (Apr 18 2023) ISSN: 1098-8785 [Electronic] United States
• PMID: 37072016 (Publication Type: Journal Article)
• Copyright: Thieme. All rights reserved.